AstraZeneca: Enhertu Improved PFS In HR-positive, HER2-low Metastatic Breast Cancer

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Monday that DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated statistically significant and clinically meaningful improvement in progression-free survival or PFS in HR- https://www.nasdaq.com/articles/astrazeneca:-enhertu-improved-pfs-in-hr-positive-her2-low-metastatic-breast-cancer